Huntsman Cancer Institute, University of Utah, Department of Radiation Oncology, Salt Lake City, UT, USA.
Intermountain Healthcare, Oncology Clinical Program, Salt Lake City, UT, USA.
Gynecol Oncol. 2014 May;133(2):250-5. doi: 10.1016/j.ygyno.2014.02.032. Epub 2014 Feb 28.
Unfavorable histology endometrial carcinomas confer worse prognosis. We determined the association of adjuvant radiation on local recurrence and survival for unfavorable, early stage endometrial cancer.
We retrospectively identified 125 patients who had a hysterectomy for early stage (FIGO IA), unfavorable histology (clear cell, papillary serous or grade 3 endometrioid), endometrial carcinoma treated between 1992 and 2011. Patients were restaged according to current FIGO 2009 guidelines. Primary endpoint was local control and secondary endpoints were distant recurrence and overall survival.
The median age of the cohort was 67 years old with a mean follow up 152 months. Adjuvant radiation was delivered in 60 patients (48%). There were a total of 24 recurrences; 5 had local-regional recurrences, 4 local and distant recurrence, 12 distant only recurrences, and 3 had unspecified recurrences. The 5-year local-regional control was 97.8% in patients who received radiation and 80.1% in patients who did not receive radiation (p=0.018). The 5-year overall survival rate was 68.1% if patients did not receive radiation and 84.9% if they did receive radiation (p=0.0062). On univariate analysis, only radiation (HR 0.12, 95% CI: 0.03 to 0.49, p-value=0.018) was associated with a significant increase in local relapse free survival.
Adjuvant radiation therapy was significantly associated with an improvement in local-regional control and overall survival in patients with unfavorable histology, early stage endometrial cancer.
组织学表现不良的子宫内膜癌预后较差。本研究旨在确定辅助放疗对组织学表现不良的早期子宫内膜癌局部复发和生存的影响。
我们回顾性分析了 1992 年至 2011 年间行子宫切除术治疗的组织学表现不良(透明细胞癌、乳头状浆液性癌或 3 级子宫内膜样癌)、FIGO 分期为 IA 期的 125 例早期子宫内膜癌患者。患者根据 2009 年 FIGO 分期标准重新分期。主要终点为局部控制,次要终点为远处复发和总生存。
本队列的中位年龄为 67 岁,平均随访时间为 152 个月。60 例(48%)患者接受了辅助放疗。共有 24 例复发;5 例局部-区域复发,4 例局部和远处复发,12 例远处复发,3 例复发部位不明。接受放疗的患者 5 年局部-区域控制率为 97.8%,未接受放疗的患者为 80.1%(p=0.018)。未接受放疗的患者 5 年总生存率为 68.1%,接受放疗的患者为 84.9%(p=0.0062)。单因素分析显示,只有放疗(HR 0.12,95%CI:0.03 至 0.49,p=0.018)与局部无复发生存率的显著提高相关。
辅助放疗可显著改善组织学表现不良、早期子宫内膜癌患者的局部区域控制和总生存。